In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Vivo Infographics

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.

Clinical Trials Commercial Market Intelligence

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

Analysis Commercial Companies

Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

BioPharmaceutical Commercial Market Intelligence

Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Innovation Pricing Strategies Reimbursement
Morphosys: Birth of a Biotech

One For All Not All For One With Personalized Therapies

Infographic: In Vivo explores trends in personalized medicine, looking at the 25 new molecular entities approved in the US last year with an individualized aspect. 

Personalized Medicine Research and Development Strategies Research & Development

PharmAI – Industry Is Smartening Up To Potential Of Artificial Intelligence

AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.

Artificial Intelligence Business Strategies Digital Health

Titans Of Pharma 2019: An Infographic Snapshot Of The Industry’s Leaders

In 2018, the 15 biggest pharma companies paid their CEOs $256m in total compensation, 2% more than they received in 2017. Find out who got paid the most, how much R&D leaders received and how median employee pay measured up, while comparing company performance.

Business Strategies Leadership Commercial

One Rare Disease Drug’s Access Journey Across The Globe

Infographic: Vertex, the first company to produce a drug to treat the underlying cause of cystic fibrosis, has fought for fair (and high) prices for its medicines to reflect their value as treatments for the cause of a genetic disease. The company has sought innovative reimbursement agreements for its CF products in various countries.

Rare Diseases Innovation Reimbursement

Drug Delivery Trends Across The Biopharma Pipeline

Exploring route of administration, mode of action, clinical trial, and therapy area trends across the biopharma pipeline.

Innovation Research and Development Strategies BioPharmaceutical

Infographic – 2018 Pharma Pipeline Snapshot

Infographic examines the current status of biopharma pipelines by trial phase, company, and therapeutic areas.

Clinical Trials Research & Development Market Intelligence
UsernamePublicRestriction

Register